SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

JERSEY CITY, N.J., Nov. 20, 2018 /PRNewswire/ -- SCYNEXIS, Inc. SCYX, a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:

• The 30^th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel on Tuesday, November 27, 2018 at 10:10 a.m. ET.
• The Evercore ISI HealthConX Conference at the Boston Harbor Hotel on Wednesday, November 28, 2018 at 11:45 a.m. ET.

Live webcasts of the presentations will be available on the Investors section of the Company's website: www.scynexis.com. Replays of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.

About SCYNEXIS
SCYNEXIS, Inc. SCYX is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations
Natalie Wildenradt
Argot Partners
Tel: 212-600-1902
natalie@argotpartners.com

Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com

SOURCE SCYNEXIS, Inc.